NCT03473574已完成2 期
A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 128
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
To determine the efficacy in terms of objective response rate (ORR) of the combination of durvalumab and tremelimumab in addition with gemcitabine or in addition with gemcitabine and cisplatin in treatment-naïve patients with advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma (CCA).
详细描述
Patients with CCA have poor outcomes, as a consequence of the very aggressive nature of the disease, and the limited treatment options. Thus there is a significant unmet medical need for additional treatment options for use in this patient population. As in most other tumor entities however, only a fraction of patients respond to immunotherapy alone. Evidence suggests that those patients might preferentially have tumors that have favorable mutational landscapes, express the PD-L1 and/ or contain preexisting tumor-infiltrating CD8+ T cells that are inhibited locally, e.g., by PD-1 engagement. In order to increase the proportion of patients who could ultimately benefit from immunotherapies, it is important to develop strategies that can be employed for converting tumor microenvironments lacking T cell infiltration to ones displaying antitumor T-cell immunity and therefore to sensitize tumors to checkpoint inhibition therapy. Therefore, the aim of this study is to determine the combination of durvalumab and tremelimumab in addition with gemcitabine or in addition with gemcitabine and cisplatin in treatment-naïve patients with advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fully-informed written consent and locally required authorization (European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- •Age ≥ 18 years.
- •Histologically documented diagnosis of cholangiocarcinoma or gall bladder carcinoma and available tumor tissue (block or at least 4 slides) for translational research.
- •Performance status (PS) ≤ 1(ECOG scale).
- •At least one measurable site of disease as defined by RECISTv1.1 criteria.
- •Adequate bone marrow and renal function including the following: Hemoglobin
- •≥ 9.0 g/dL; absolute neutrophil count ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9 /L; Creatinine ≤ 1.5 x upper normal limit.
- •Calculated creatinine clearance ≥40 mL/min as determined by the Cockcroft- Gault equation (using actual body weight)
- •Adequate hepatic function (with stenting for any obstruction, if required) including the following: Total bilirubin ≤ 2x upper normal limit; AST (SGOT), ALT (SGPT) ≤ 5 x upper normal limit; prothrombin time ≥ 60%; albumin ≥ 30 g/L.
- •Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- •Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- •Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- •The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
排除标准
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study
- •Participation in another clinical study with an investigational product within 21 days prior to the first dose of the study treatment.
- •Prior immunotherapy or use of other investigational agents, including prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T-lymphocyte associated antigen-4 (anti-CTLA-4) antibody, therapeutic cancer vaccines.
- •Prior chemotherapy with gemcitabine, Cisplatin and/or capecitabine (exception: gemcitabine, cisplatind and/or capecitabine in the adjuvant setting, last infusion has to be ≥ 6 months prior randomization).
- •Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
- •Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable. Note: Local treatment of isolated lesions for palliative intent is acceptable (eg, local radiotherapy).
- •Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drugs.
- •Major surgery (as defined by the Investigator) within 4 weeks prior to the first dose of the investigational product (IMP) of starting the study and patients must have recovered from effects of major surgery. Note: Local non-major surgery for palliative intent (eg, surgery of isolated lesions, per-cutaneous biliary drainage or biliary stenting) is acceptable.
- •History of allogenic organ transplantation.
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).
- •The following are exceptions to this criterion:
- •Patients with vitiligo or alopecia
- •Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
- •Any chronic skin condition that does not require systemic therapy
- •Patients without active disease in the last 5 years may be included but only after consultation with the study physician
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- •History of another primary malignancy except for:
- •Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IMP and of low potential risk for recurrence
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated carcinoma in situ without evidence of disease
- •History of leptomeningeal carcinomatosis
- •Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have a CT/ MRI of the brain prior to study entry.
- •History of active primary immunodeficiency
- •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen [HBsAg) result], hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
- •Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- •Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP.
- •Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMP and up to 30 days after the last dose of IMP.
- •Body weight ≤30 kg.
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of tremelimumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.
- •Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product.
- •Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
- •Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- •Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
研究组 & 干预措施
Arm D
Experimental
Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
干预措施: Tremelimumab (Biological)
Arm A
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
干预措施: Durvalumab (Biological)
Arm A
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
干预措施: Gemcitabine (Drug)
Arm A
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
干预措施: Tremelimumab (Biological)
Arm B
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
干预措施: Durvalumab (Biological)
Arm B
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
干预措施: Gemcitabine (Drug)
Arm B
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
干预措施: Cisplatin (Drug)
Arm B
Experimental
Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
干预措施: Tremelimumab (Biological)
Arm C
Other
Gemcitabine in combination with Cisplatin
干预措施: Gemcitabine (Drug)
Arm C
Other
Gemcitabine in combination with Cisplatin
干预措施: Cisplatin (Drug)
Arm D
Experimental
Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
干预措施: Durvalumab (Biological)
Arm D
Experimental
Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
干预措施: Gemcitabine (Drug)
Arm D
Experimental
Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
干预措施: Cisplatin (Drug)
Arm E
Experimental
Durvalumab in combination with Gemcitabine and Cisplatin
干预措施: Durvalumab (Biological)
Arm E
Experimental
Durvalumab in combination with Gemcitabine and Cisplatin
干预措施: Gemcitabine (Drug)
Arm E
Experimental
Durvalumab in combination with Gemcitabine and Cisplatin
干预措施: Cisplatin (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 30 months
Response Rate (RR) according to RECIST V1.1
次要结局
- Overall survival (OS)(max observation period 30 months)
- Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.0 (Safety and Tolerability)(30 months)
- Quality of Life(30 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaMetastatic Adult Soft Tissue SarcomaRecurrent Adult Soft Tissue SarcomaNCT03317457AIO-Studien-gGmbH103
进行中（未招募）
1 期
A study to investigate whether treatment of bile duct or gallbladder cancer with Durvalumab and Tremelimumab in combination with gemcitabine alone or with gemcitabine and cisplatin is more effective in comparison to standard chemotherapy with gemcitabine and cisplatin.advanced, unresectable and/or metastatic cholangio- and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017617Term: Gallbladder cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025941Term: Malignant neoplasm of gallbladder and extrahepatic bile ductsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025940Term: Malignant neoplasm of gallbladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10007426Term: Carcinoma of gallbladderSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10017622Term: Gallbladder carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025943Term: Malignant neoplasm of gallbladder and extrahepatic bile ducts non-resectableSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10077744Term: Adenocarcinoma of gallbladder metastaticSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10077847Term: Gallbladder adenocarcinoma metastaticSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2017-001538-25-DEAIO-Studien-gGmbH128
已完成
2 期
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary TractNon-Transitional Cell Carcinoma of the Urothelial TractSmall Cell of the BladderAdenocarcinoma of the BladderSquamous Cell Carcinoma of the BladderMetastatic Bladder CancerNCT03430895Memorial Sloan Kettering Cancer Center15
进行中（未招募）
2 期
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.EGFR Mutant Advanced Non Small Cell Lung CancerNCT03994393University of Sydney100
进行中（未招募）
2 期
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASCarcinoma, Non-Small-Cell LungNCT06008093AstraZeneca103